Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.
A rabbit model for Staphylococcus aureus osteomyelitis was used to compare the results of treatment with A-56619 and A-56620, two new aryl-fluoroquinolones, and nafcillin. A-56619 (15 mg/kg) and A-56620 (20 mg/kg), both used for 28 days of treatment, were injected subcutaneously every 12 h, and nafcillin (40 mg/kg) was injected every 6 h. After treatment, S. aureus was found on bone marrow cultures from 19 of 20 control rabbits, 6 of 20 treated with A-56619, 14 of 20 treated with A-56620, and 8 of 20 treated with nafcillin. Drug concentrations in serum and uninfected and infected bone were measured 1 h after A-56619 and A-56620 injection and 30 min after nafcillin injection in a group of rabbits that had been infected for 3 to 4 weeks. The concentrations in infected bone were similar for all three drugs and were significantly higher than in uninfected bone. The results of this study showed that A-56619 had a high rate of eradication of S. aureus from infected bone and compared favorably to nafcillin.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001842:Bone and Bones / Q000032:analysis / Q000382:microbiology; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D024841:Fluoroquinolones; D009254:Nafcillin / Q000378:metabolism / Q000627:therapeutic use*; D010019:Osteomyelitis / Q000188:drug therapy*; D011817:Rabbits; D011897:Random Allocation; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009254:Nafcillin; D002939:Ciprofloxacin; C047225:difloxacin; C047224:sarafloxacin